India has developed its first indigenously discovered antibiotic “Nafithromycin”, which is effective against resistant respiratory infections, particularly useful for cancer patients and poorly controlled diabetics. Union Minister of State for Science & Technology Dr. Jitendra Singh said this antibiotic is the first molecule entirely conceptualised, developed and clinically validated in India, representing a significant leap toward self-reliance in the pharmaceutical sector.

Nafithromycin is a new ketolide antibiotic primarily used to treat drug-resistant respiratory infections, most notably community-acquired bacterial pneumonia (CABP). Its benefits stem from its enhanced efficacy against resistant bacteria, a shorter treatment regimen, and a favorable safety profile compared to older antibiotics.

The antibiotic Nafithromycin has been developed by the Govt of India’s Department of Biotechnology in collaboration with well-known private pharma house Wockhardt. Nafithromycin marks a significant milestone in India’s journey toward innovation-driven healthcare solutions, setting a benchmark in combating antimicrobial resistance.

Key Features of Nafithromycin

Short Treatment Duration: A three-day regimen offering 10 times the efficacy of existing antibiotics.

Broad-Spectrum Action: Targets both typical and atypical pathogens, addressing limitations of antibiotics like azithromycin.

Improved Safety Profile: Minimal gastrointestinal side effects, no significant drug interactions, and unaffected by food consumption.

Global First in 30 Years: Nafithromycin is the first new antibiotic in its class globally in over three decades.

Nafithromycin benefits

Nafithromycin is designed to overcome common resistance mechanisms that impact older macrolides, like azithromycin. It is reported to be up to 10 times more effective than azithromycin against resistant bacterial strains. The drug is potent against a broad spectrum of pathogens that cause respiratory infections, including both typical (e.g., Streptococcus pneumoniae) and atypical (e.g., Mycoplasma pneumoniae and Chlamydia pneumoniae) bacteria. It is particularly effective against multi-drug-resistant (MDR) strains.

Clinical trials have shown that a 3-day course of once-daily oral nafithromycin is as effective as a 7-day course of moxifloxacin for treating CABP. This shorter regimen improves patient compliance and reduces the overall use of antibiotics. The antibiotic achieves high and sustained concentrations in lung tissues, reaching levels eight times higher than azithromycin. This makes it exceptionally effective for treating lung infections like pneumonia.

Nafithromycin is generally well-tolerated with a low risk of significant side effects or drug-drug interactions compared to some other antibiotics, like fluoroquinolones. This makes it a safer option for vulnerable patients, such as the elderly. The antibiotic has anti-inflammatory properties in addition to its antibacterial effects. This immunomodulatory activity may provide additional benefits by resolving secondary complications associated with severe pneumonia.

Ongoing research is exploring Nafithromycin’s potential use against other infections, including skin and soft tissue infections, and its possible role in treating lung cancer due to its interactions with cancer-related proteins.

India must develop self-sustainable ecosystem for scientific & research growth: Dr Jitendra Singh

Citing this as an example of successful industry-academia partnership driving India’s biopharmaceutical growth, the Union Minister emphasised the need to build a self-sustainable innovation ecosystem, so that India could reduce its dependence on government funding and create a culture of private sector participation and philanthropic support to achieve global recognition in research and innovation.

Inaugurating the 3-day Medical Workshop on “Harnessing Artificial Intelligence for Multi-Omics Data Integration and Analysis”, Dr. Jitendra Singh said that India must develop a self-sustainable ecosystem to drive its scientific and research growth. He stated that most nations that have achieved global recognition in science and innovation have done so through self-sustaining, innovation-driven models with extensive engagement of the private sector.

Citing another successful story of government – non government collaboration, the Minister also announced that India has achieved a major breakthrough in gene therapy, marking the first successful indigenous clinical trial for Hemophilia treatment, the trial for which was supported by Govt of India’s Department of Biotechnology and done in a non-government sector hospital, Christian Medical College Vellore.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share